The Biotechnology Industry Research Assistance Council (BIRAC), under
its advanced technology scheme, Biotechnology Industry Partnership
Programme (BIPP), has invited fresh proposals from biotech companies for
support on a cost sharing basis targeted at development of novel and
high risk futuristic technologies mainly for viability gap funding and
enhancing existing R&D capacities of Start-ups and SMEs in key areas
of national importance and public good.
BIRAC, a not-for-profit public sector undertaking set up by Department of Biotechnology (DBT), is running this scheme to promote and nurture innovation research in biotech enterprises specially start-ups and SMEs. Major thrust of the programme is towards funding technologies which address a major national problem and/or involves high level of innovation. The proposals spanning across the spectrum of pre-proof-of-concept to validation of established technologies are considered for support in the form of grant and/or loan.
The scheme supports large, medium, small scale companies as well as start-up on cost sharing basis. It would push for high risk, discovery linked innovation and accelerated technology development. Varying models of grants, loans or grant plus loans will be made available under the scheme. It will be one of the most enabling mechanisms to promote R&D in biotech industry and public private partnership programmes.
BIRAC, a not-for-profit public sector undertaking set up by Department of Biotechnology (DBT), is running this scheme to promote and nurture innovation research in biotech enterprises specially start-ups and SMEs. Major thrust of the programme is towards funding technologies which address a major national problem and/or involves high level of innovation. The proposals spanning across the spectrum of pre-proof-of-concept to validation of established technologies are considered for support in the form of grant and/or loan.
The scheme supports large, medium, small scale companies as well as start-up on cost sharing basis. It would push for high risk, discovery linked innovation and accelerated technology development. Varying models of grants, loans or grant plus loans will be made available under the scheme. It will be one of the most enabling mechanisms to promote R&D in biotech industry and public private partnership programmes.
No comments:
Post a Comment